SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Helium is a decentralized machine network powered by a physical blockchain. The network is created by gateways who also double as miners on our network. These gateway operators can earn tokens based on coverage they provide as well as transaction fees gained from machines connecting to their gateway  Helium is a new cryptocurrency. Hotspots earn for providing and validating wireless coverage and when devices on the network connect to the internet through Hospots  Helium is mined and distributed to Hotspot Owners, Helium Inc, and investors. There is no pre-mine of Helium, and every month approximately 5,000,000 new Helium are minted.  At the end of each mining period, roughly every 30 to 60 mins, Helium is distributed according to the allocation shown:

Helium

Heliums rally is being tied primarily to reported adoption by Celina, Texas, where the city is using the Helium networksupporting the broader DePIN and real-world wireless utility narrative. Bullish traders view the development as fuel for continued momentum and a possible short squeeze, while skeptics point to weak hotspot economics, dilution, and management concerns.

SELLAS Life Sciences Group, Inc. is a clinical stage biopharmaceutical company, which engages in the development and commercialization of immunotherapeutic for cancer indications. Its product pipeline includes galinpepimut-S. The company was founded by Angelos M. Stergiou on April 3, 2006 and is headquartered in New York, NY.

SELLAS Life Sciences Group Inc

A BMF short report questioning the statistical power, control arm, and valuation of SELLASs REGAL Phase 3 AML trial drove attention and selling pressure. Traders remain divided: bears see meaningful downside risk if the trial fails, while bulls dismiss the report and focus on the pending 80th-event announcement and topline readout as potential catalysts.

Johnson & Johnson is a holding company, which engages in the research, development, manufacture, and sale of products in the healthcare field. It operates through the Innovative Medicine and MedTech segments. The Innovative Medicine segment focuses on immunology, infectious diseases, neuroscience, oncology, cardiovascular and metabolism, and pulmonary hypertension. The MedTech segment includes a portfolio of products used in interventional solutions, orthopaedics, surgery, and vision categories. The company was founded by Robert Wood Johnson I, James Wood Johnson, and Edward Mead Johnson Sr. in 1887 and is headquartered in New Brunswick, NJ.

Johnson & Johnson

A stronger-than-expected quarterly update and higher full-year outlook, combined with broad rotation into healthcare defensives, are driving attention toward Johnson & Johnson. Traders are balancing growth in Innovative Medicine and new products against MedTech softness, patent erosion and lingering talc-related liabilities.

Red Cat Holdings, Inc. provides products, services and solutions to the drone industry. It also engages in the provision of distributed data storage, analytics and services for the drone industry.The firm product include Dronebox, which is a blockchain technology that records, stores and analyzes flight data and information from a drone. It operates through the Enterprise Segment. The Enterprise Segment will focus on developing a hardware enabled software platform of services and solutions to government and commercial enterprises and the military. The company was founded by Jeffrey M. Thompson in February 1984 and is headquartered in San Juan, Puerto Rico.

Red Cat Holdings Inc

U.S. tariffs on foreign-made drones and components, alongside anticipated Pentagon spending on domestic drone production, are driving attention to Red Cat as a potential beneficiary. Traders remain divided, with bulls expecting contract awards and Gauntlet II-related momentum, while skeptics point to the lack of confirmed major orders, ongoing losses, dilution, and managements promotional commentary.

Merck & Co., Inc. is a health care company, which engages in the provision of health solutions through its prescription medicines, vaccines, biologic therapies, animal health, and consumer care products. It operates through the following segments: Pharmaceutical, Animal Health, and Other. The Pharmaceutical segment includes human health pharmaceutical and vaccine products. The Animal Health segment discovers, develops, manufactures, and markets animal health products, such as pharmaceutical and vaccine products, for the prevention, treatment and control of disease in livestock, and companion animal species. The Other segment consists of sales for the non-reportable segments of healthcare services. The company was founded in 1891 and is headquartered in Rahway, NJ.

Merck & Co Inc

Merck and Modernas personalized mRNA cancer vaccine, used with Keytruda, met key Phase 3 recurrence and metastasis endpoints in resected melanoma, renewing enthusiasm for Mercks oncology pipeline and helping drive the shares to new highs. Traders remain divided over how much of the opportunity is already priced in, with pending full data, regulatory review, manufacturing complexity and Keytrudas eventual patent expiry cited as risks.

Vanguard Index Funds - Vanguard Morningstar Total Stock Market ETF

Vanguard Total Stock Market ETF

Broad-market diversification and buy-and-hold investing are driving attention, with traders describing VTI as a core portfolio anchor and defensive option amid volatility. Others debate its heavy exposure to mega-cap technology and warn that an AI correction, rising rates, debt concerns, and geopolitical risk could pressure the broader index.

Energy Fuels, Inc. is a mining development company, which engages in the exploration and evaluation of uranium and vanadium properties. It operates through the following segments: Uranium, Rare Earth Elements (REE), and Heavy Mineral Sands (HMS). The uranium segment engages in conventional and ISR uranium extraction, recovery and sales of uranium from mineral properties and the recycling of uranium-bearing materials generated by third parties along with the exploration, permitting and evaluation of uranium properties in the U.S. The REE segment is engaged in the company’s initiatives to progress towards full REE separation capabilities at the Mill to produce both light and heavy separated REE oxides in the coming years. The HMS segment engages in the exploration, development and recovery of HMS at the Kwale Project, Bahia Project, Vara Mada Project and the company’s equity method investments in the Donald Project JV and Tate. The company was founded by George E. L. Glasier and John David Mason on June 24, 1987 and is headquartered in Lakewood, CO.

Energy Fuels Inc

Energy Fuels completed acquisition of Australian Strategic Materials, including the Korean Metals Plant, is fueling discussion about its strategy to build a Western mine-to-magnet rare-earth supply chain alongside its uranium business. Traders are divided between those focused on the strategic minerals, defense and nuclear upside and those frustrated by weak price action, execution risks and profitability concerns.

iShares Trust - iShares 20+ Year Treasury Bond ETF

iShares 20+ Year Treasury Bond ETF

Treasury Secretary Scott Bessents expanded long-duration Treasury buyback plan is driving attention, with traders speculating it could suppress yields and trigger a short squeeze in TLT. Skeptics argue the intervention is too small to overcome persistent inflation, heavy borrowing and hawkish Fed signals, leaving long-term yieldsand TLTvolatile.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Visas monitoring of Hims & Hers over elevated credit-card disputes tied to its weight-loss subscriptions, alongside ongoing FTC scrutiny, is driving attention and the sharp selloff. Traders disagree on whether the issues are an overblown near-term shock or could force costly changes to the business and weigh on customer confidence, while long-term bulls remain focused on GLP-1, peptide, and telehealth growth.

SPDR Series Trust - State Street SPDR S&P Biotech ETF

SPDR S&P Biotech ETF

A broad biotech rotation and renewed interest in the sectorhighlighted by Moderna and Mercks positive personalized cancer-vaccine datahas driven much of the attention around XBI. Traders remain divided over whether the rally can continue, with higher Treasury yields and rate-hike concerns blamed for sharp pullbacks in the rate-sensitive ETF.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Verastem (VSTM) Reports Q2 Loss, Beats Revenue Estimates

Verastem (VSTM) delivered earnings and revenue surprises of +23.91% and +73.12%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Reports Second Quarter 2026 Financial Results and Highlights Recent Business Updates

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today reported financial results for the second quarter ended June 30, 2026, and highlighted recent business progress. The second quarter marked...

Royalty Pharma (RPRX) Tops Q2 Earnings and Revenue Estimates

Royalty Pharma (RPRX) delivered earnings and revenue surprises of +3.94% and +1.52%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Dianthus Therapeutics, Inc. (DNTH) Reports Q2 Loss, Tops Revenue Estimates

Dianthus Therapeutics, Inc. (DNTH) delivered earnings and revenue surprises of +3.23% and +60.89%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Reports Q2 Loss, Tops Revenue Estimates

Guardant Health (GH) delivered earnings and revenue surprises of -5.00% and +6.01%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Adaptive Biotechnologies (ADPT) Reports Q2 Loss, Beats Revenue Estimates

Adaptive Biotechnologies (ADPT) delivered earnings and revenue surprises of +23.08% and +7.98%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

Verastem Oncology Doses First Patient in TARGET-D 203 Phase 2 Registration-Directed Trial of VS-7375 Oral KRAS G12D (ON/OFF) Inhibitor for KRAS G12D-Mutated Metastatic Colorectal Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 203 Phase 2 registration-directed trial evaluating VS-7375, an investigational...

Verastem Oncology to Report Second Quarter 2026 Financial Results on August 6, 2026

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the Company will host a conference call and webcast to discuss its second quarter 2026 financial results and business updates on...

Verastem Oncology Doses First Patient in TARGET-D 202 Phase 2 Registration-Directed Trial of VS-7375 for KRAS G12D-Mutated Advanced Non-Small Cell Lung Cancer

Verastem Oncology (Nasdaq: VSTM), a biopharmaceutical company committed to advancing new medicines for patients with RAS/MAPK pathway-driven cancers, today announced that the first patient has been dosed in the TARGET-D 202 Phase 2 registration-directed trial evaluating VS-7375, an investigational...

RBC Capital Reaffirms Outperform Rating For Verastem (VSTM)

RBC Capital Reaffirms Outperform Rating For Verastem (VSTM...

• Reported GAAP EPS of -$0.35 up 10.26% YoY
• Reported revenue of $40.08M up 1775.43% YoY

Verastem, Inc. faces substantial doubt regarding its ability to continue as a going concern, driven by significant accumulated deficits and ongoing losses while operating in a highly competitive market.

Verastem, Inc. demonstrated significant commercial growth for AVMAPKI FAKZYNJA CO-PACK, achieved a key $15.0 million milestone payment, and continued to advance its clinical-stage pipeline programs during the quarter.

Verastem, Inc. is a biopharmaceutical company, which engages in the development and commercialization of drugs for the treatment of cancer. The company was founded by Richard H. Aldrich, Michelle Dipp, Piyush Gupta, Satish Jindal, Eric S. Lander, Robert F. Weinberg, and Christoph H. Westphal on August 4, 2010 and is headquartered in Needham, MA.

Verastem Inc

VSTM Stock Climbs After-Hours As FDA Grants Fast Track To Lung Cancer Drug — Retail Eyes The Next Keytruda 

Equity

Neutral Sentiment

Up more than 1%

Flat to up 1%

Flat to down 1%

Down more than 1%

The S&P 500 ($SPY) is headed towards a positive week. What do you think the index's return will look like next week? Vote and explain your reasoning in the comments.

What do you think the S&amp;P 500&#39;s ($SPY) return will be next week?

Feed

News

Sentiment

Earnings

Fundamentals

Info

VSTM Verastem Inc

Fundamentals

Connect Stocktwits to ChatGPT

Latest VSTM News